Inflammatory gene expression modulation

Inflammatory gene expression modulation refers to the regulation of gene activity—primarily transcriptional and post-transcriptional—of genes that mediate inflammatory responses. This process involves a network of signaling pathways and molecular regulators (such as transcription factors like NF-κB, STATs, IRFs; RNA-binding proteins including TTP, Roquin, Regnase-1; and chromatin remodelers) that control the induction, repression, or fine-tuning of pro-inflammatory and anti-inflammatory genes. Drugs targeting these regulatory pathways often do so by inhibiting key transcription factors, stabilizing mRNA, or altering chromatin structure, and are cornerstone therapies in many autoimmune, inflammatory, and infectious diseases. However, modulation of inflammatory gene expression is not a single druggable entity—it comprises numerous individual molecular targets and mechanisms[1][2][3][4][5].

Inhibition or activation of transcription factors binding to pro-inflammatory gene promoters; Epigenetic regulation of chromatin accessibility and gene expression; RNA-binding proteins promoting or inhibiting mRNA stability; Chromatin remodeling; Signaling pathway modulation (e.g., NF-κB, JAK/STAT1)